Abstract
The efficacies of the new quinolones temafloxacin, ofloxacin, and ciprofloxacin were investigated against Mycoplasma pneumoniae in an experimental hamster pneumonia model. Hamsters were infected intratracheally with M. pneumoniae and sacrificed 18 h after the final medication, and their lungs were aseptically removed, homogenized, and cultured quantitatively. The efficacies of these drugs were determined by the CFU of M. pneumoniae in lungs. Temafloxacin and ofloxacin, but not ciprofloxacin, were active when the oral administration of 200 mg/kg of body weight per day (once per day) for 5 days was initiated 24 h after infection. Although no effect on the elimination of M. pneumoniae was observed after the administration of these drugs at 200 mg/kg/day at 5 days after infection, the continuous administration for 15 days of temafloxacin, but not ofloxacin or ciprofloxacin, significantly reduced viable M. pneumoniae in the lungs. These results suggest that temafloxacin and ofloxacin are effective in the acute phase of infection and, moreover, that temafloxacin is effective in the late stage of infection during which progressive lung alterations and continuous increases in mycoplasmal growth occurred. The peak levels of temafloxacin in sera and lungs after oral administration were similar to those of ofloxacin and higher than those of ciprofloxacin. The areas under the curve of temafloxacin in the lung tissue, however, were higher than those of ofloxacin and ciprofloxacin. On the basis of these results, temafloxacin and ofloxacin might be promising antimicrobial agents for the treatment of mycoplasmal infection.
Full text
PDF





Images in this article
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Arai S., Gohara Y., Kuwano K., Kawashima T. Antimycoplasmal activities of new quinolones, tetracyclines, and macrolides against Mycoplasma pneumoniae. Antimicrob Agents Chemother. 1992 Jun;36(6):1322–1324. doi: 10.1128/aac.36.6.1322. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Azoulay-Dupuis E., Bedos J. P., Vallée E., Hardy D. J., Swanson R. N., Pocidalo J. J. Antipneumococcal activity of ciprofloxacin, ofloxacin, and temafloxacin in an experimental mouse pneumonia model at various stages of the disease. J Infect Dis. 1991 Feb;163(2):319–324. doi: 10.1093/infdis/163.2.319. [DOI] [PubMed] [Google Scholar]
- Barile M. F., Chandler D. K., Yoshida H., Grabowski M. W., Harasawa R., Razin S. Parameters of Mycoplasma pneumoniae infection in Syrian hamsters. Infect Immun. 1988 Sep;56(9):2443–2449. doi: 10.1128/iai.56.9.2443-2449.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Cassell G. H., Waites K. B., Pate M. S., Canupp K. C., Duffy L. B. Comparative susceptibility of Mycoplasma pneumoniae to erythromycin, ciprofloxacin, and lomefloxacin. Diagn Microbiol Infect Dis. 1989 Sep-Oct;12(5):433–435. doi: 10.1016/0732-8893(89)90115-6. [DOI] [PubMed] [Google Scholar]
- Clyde W. A., Jr Immunopathology of experimental Mycoplasma pneumoniae disease. Infect Immun. 1971 Dec;4(6):757–763. doi: 10.1128/iai.4.6.757-763.1971. [DOI] [PMC free article] [PubMed] [Google Scholar]
- DOWDLE W. R., ROBINSON R. Q. AN INDIRECT HEMAGGLUTINATION TEST FOR DIAGNOSIS OF MYCOPLASMA PNEUMONIAE INFECTIONS. Proc Soc Exp Biol Med. 1964 Aug-Sep;116:947–950. doi: 10.3181/00379727-116-29416. [DOI] [PubMed] [Google Scholar]
- Fernald G. W., Clyde W. A., Jr, Bienenstock J. Immunoglobulin-containing cells in lungs of hamsters infected with Mycoplasma pneumoniae. J Immunol. 1972 May;108(5):1400–1408. [PubMed] [Google Scholar]
- Fernandes P. B., Chu D. T., Bower R. R., Jarvis K. P., Ramer N. R., Shipkowitz N. In vivo evaluation of A-56619 (difloxacin) and A-56620: new aryl-fluoroquinolones. Antimicrob Agents Chemother. 1986 Feb;29(2):201–208. doi: 10.1128/aac.29.2.201. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Hardy D. J., Swanson R. N., Hensey D. M., Ramer N. R., Bower R. R., Hanson C. W., Chu D. T., Fernandes P. B. Comparative antibacterial activities of temafloxacin hydrochloride (A-62254) and two reference fluoroquinolones. Antimicrob Agents Chemother. 1987 Nov;31(11):1768–1774. doi: 10.1128/aac.31.11.1768. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Hooper D. C., Wolfson J. S. The fluoroquinolones: pharmacology, clinical uses, and toxicities in humans. Antimicrob Agents Chemother. 1985 Nov;28(5):716–721. doi: 10.1128/aac.28.5.716. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Misu T., Arai S., Furukawa M., Yamamoto Y., Miyazaki T. Effects of rokitamycin and other macrolide antibiotics on Mycoplasma pneumoniae in L cells. Antimicrob Agents Chemother. 1987 Nov;31(11):1843–1845. doi: 10.1128/aac.31.11.1843. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Niitu Y., Hasegawa S., Suetake T., Kubota H., Komatsu S., Horikawa M. Resistance of Mycoplasma pneumoniae to erythromycin and other antibiotics. J Pediatr. 1970 Mar;76(3):438–443. doi: 10.1016/s0022-3476(70)80485-1. [DOI] [PubMed] [Google Scholar]
- Nitu Y., Hasegawa S., Kubota H. In vitro development of resistance to erythromycin, other macrolide antibiotics, and lincomycin in Mycoplasma pneumoniae. Antimicrob Agents Chemother. 1974 May;5(5):513–519. doi: 10.1128/aac.5.5.513. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Osada Y., Ogawa H. Antimycoplasmal activity of ofloxacin (DL-8280). Antimicrob Agents Chemother. 1983 Mar;23(3):509–511. doi: 10.1128/aac.23.3.509. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Sorgel F., Naber K. G., Kinzig M., Mahr G., Muth P. Comparative pharmacokinetics of ciprofloxacin and temafloxacin in humans: a review. Am J Med. 1991 Dec 30;91(6A):51S–66S. doi: 10.1016/0002-9343(91)90312-l. [DOI] [PubMed] [Google Scholar]
- Swanson R. N., Hardy D. J., Chu D. T., Shipkowitz N. L., Clement J. J. Activity of temafloxacin against respiratory pathogens. Antimicrob Agents Chemother. 1991 Mar;35(3):423–429. doi: 10.1128/aac.35.3.423. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Sörgel F., Jaehde U., Naber K., Stephan U. Pharmacokinetic disposition of quinolones in human body fluids and tissues. Clin Pharmacokinet. 1989;16 (Suppl 1):5–24. doi: 10.2165/00003088-198900161-00004. [DOI] [PubMed] [Google Scholar]
- Taylor-Robinson D., Purcell R. H., Wong D. C., Chanock R. M. A colour test for the measurement of antibody to certain mycoplasma species based upon the inhibition of acid production. J Hyg (Lond) 1966 Mar;64(1):91–104. doi: 10.1017/s0022172400040377. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Waites K. B., Cassell G. H., Canupp K. C., Fernandes P. B. In vitro susceptibilities of mycoplasmas and ureaplasmas to new macrolides and aryl-fluoroquinolones. Antimicrob Agents Chemother. 1988 Oct;32(10):1500–1502. doi: 10.1128/aac.32.10.1500. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Wenzel R. P., Hendley J. O., Dodd W. K., Gwaltney J. M. Comparison of josamycin and erythromycin in the therapy of Mycoplasma pneumoniae pneumonia. Antimicrob Agents Chemother. 1976 Dec;10(6):899–901. doi: 10.1128/aac.10.6.899. [DOI] [PMC free article] [PubMed] [Google Scholar]